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According to established notion, one of the major angiogenesis-inducing factors, pro-matrix metalloproteinase-9
(proMMP-9), is supplied to the tumor microenvironment by tumor-associated macrophages (TAMs). Accumulated
evidence, however, indicates that tumor-associated neutrophils (TANs) are also critically important for proMMP-9
delivery, especially at early stages of tumor development. To clarify how much angiogenic proMMP-9 is actually
contributed by TAMs and TANs, we quantitatively evaluated TAMs and TANs from different tumor types, including
human xenografts and syngeneic murine tumors grown in wild-type and Mmp9-knockout mice. Whereas host
MMP-9 competence was required for full angiogenic potential of both normal and tumor-associated leukocytes,
direct comparisons of neutrophils versus macrophages and TANs versus TAMs demonstrated that macrophages
and TAMs secrete 40- to 50-fold less proMMP-9 than the same numbers of neutrophils or TANs. Correspondingly,
the levels of MMP-9–mediated in vivo angiogenesis induced by neutrophils and TANs substantially exceeded those
induced by macrophages and TAMs. MMP-9–delivering TANs were also required for development of metastasis-
supporting intratumoral vasculature, characterized by ≥11-μm size lumens and partial coverage with stabilizing
pericytes. Importantly, MMP-9–producing TAMs exhibit M2-skewed phenotype but do not express tissue inhibitor of
metalloproteinases-1 (TIMP-1), a novel characteristic allowing them to secrete TIMP-1–free, neutrophil-like MMP-9
zymogen unencumbered by its natural inhibitor. Together, our findings support the notion whereby TANs, capable of
immediate release of their pre-stored cargo, are the major contributors of highly angiogenic MMP-9, whereas tumor-
influxing precursors of macrophages require time to differentiate, polarize into M2-skewed TAMs, shut down their
TIMP-1 expression, and only then, initiate relatively low-level production of TIMP-free MMP-9 zymogen.
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Neutrophils and macrophages represent leukocytes with diversified
functions in immune surveillance and inflammatory responses in tissues
[1,2]. These two types of infiltrating leukocytes have also been
implicated in regulating tumor development and angiogenesis [3–5],
although the role of tumor-associatedmacrophages (TAMs) has been in
a favored focus of cancer research for many years [6–9], whereas the
critical functions of tumor-associated neutrophils (TANs) have only
recently become appreciated [10–15].
Cancer metastasis depends on the induction of an angiogenic
vasculature that in addition to nutrient supply provides structural
conduits for tumor cell dissemination [16–18]. It has been demonstrated
that matrix metalloproteinase-9 (MMP-9) plays a critical role in tumor
angiogenesis and metastasis by turning on the angiogenic switch in
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of distinct neovascular networks sustaining tumor cell intravasation [20].
Angiogenesis-inducing MMP-9 is supplied to the tumor microenviron-
ment as a zymogen, proMMP-9, mostly by bone marrow–derived
(BMD) myeloid cells, including TAMs and TANs [21], but the
regulation of MMP-9 angiogenic activity remains unresolved.
Although a link between tumor-infiltrating leukocytes and their
supplied MMP-9 has been shown [22–27], it has never been determined
how much of proMMP-9 is actually contributed by a specific
inflammatory cell type to tumor angiogenesis as well as what is the status
or formof the deliveredMMP-9.Depending on a particular cancermodel,
the angiogenesis-inducing MMP-9 was attributed to different types of
tumor-infiltrating leucocytes. Thus, mast cells were shown to contribute
their MMP-9 in the skin carcinogenesis model [22]. Pharmacological
depletion of macrophages has emphasized a critical importance of TAMs
in tumor growth and angiogenesis, mainly through vascular endothelial
growth factor–involvingmechanisms [28–31]. Furthermore, in themouse
model of cervical cancer, TAMswere creditedwith the supplementation
of angiogenesis-switching proMMP-9 [32]. Accumulated evidence
from our laboratory and others further indicated that neutrophils can
more effectively supply their proMMP-9, which is uniquely free of
tissue inhibitor of metalloproteinases-1 (TIMP-1), to potently induce
angiogenesis in normal and pathophysiological environments [33–38].
Most recently, we have provided evidence that human M2
macrophages produce angiogenic proMMP-9, whereas M1 macro-
phages secrete low or non-angiogenic proMMP-9 [39]. Moreover, the
angiogenesis-inducing capacity of proMMP-9 produced by M2
macrophages has been linked to its neutrophil-like, TIMP-free status
since expression of TIMP-1 is rapidly and specifically shut down during
M2 polarization [39]. This unique form of proMMP-9 secreted by
physiologically normal M2 macrophages raised a cancer-related
question regarding whether TAMs also produce TIMP-free
proMMP-9 to induce angiogenesis within primary tumors, a notion
that was directly addressed in this study. In addition, we thought to
clarify whether TANs or TAMs, or both, serve as a main contributor of
the angiogenic proMMP-9 within the tumor microenvironment.
By using a panel ofmurine and human tumors developing inMMP-9–
competent and MMP-9–knockout mice (Mmp9-KO), we conducted
quantitative biochemical, kinetic, and functional comparisons of TANs
and TAMs and their proMMP-9. We have demonstrated that similar to
inflammatory neutrophils and TANs, the proMMP-9 secreted by M2-
skewed TAMs is TIMP-free, conferring it with angiogenesis-inducing
capacity. Furthermore, although intact TANs and TAMs were both
capable of inducing angiogenesis, the angiogenic potential of TAMs was
much lower than that of TANs, which correlated with low levels of
proMMP-9 secreted by TAMs even over long-time periods versus copious
amounts released byTANs immediately on demand. Therefore, our data,
which do not dispute the important role of TAMs in tumor development,
nevertheless indicate that TANs constitute the dominant cell source of
highly angiogenic proMMP-9. Thus, neutrophilMMP-9might serve as a
therapeutic target in human cancers in which early or chronic neutrophil
infiltration is associated with enhanced tumor angiogenesis and
poor prognosis.
Materials and Methods
Cell Lines and Culture Conditions
High- and low-disseminating variants of human prostate
carcinoma, PC-hi/diss and PC-lo/diss [40], were generated fromthe parental cell line, PC-3, purchased from American Type Culture
Collection (Manassas, VA). Murine L929 fibrosarcoma, B16-F10
melanoma (B16), and Lewis lung carcinoma (LLC) were from ATCC.
All tumor cell lines were routinely tested and confirmed to be negative
for mycoplasma and bacterial contamination and were used within 6
months after thawing low-passage frozen stocks. Tumor cells were
cultured in Dulbecco's modified Eagle's medium (DMEM), supple-
mented with 10% FBS and 10 μg/ml gentamicin (D10), and passaged
at confluence by a brief exposure to trypsin/EDTA.
Isolation of Murine Neutrophils from Peripheral Blood and
Bone Marrow
All animal work was conducted in accordance to the animal protocol
approved by the Institutional Animal Care and Use Committee of The
Scripps Research Institute (TSRI, La Jolla, CA). Wild-type (WT)
C57BL/6micewere purchased fromTSRI breeding colony at the age of 2
to 3 months. The Mmp9-KO mice on C57BL/6 background were
purchased from Jackson Laboratories (BarHarbor,ME) and bred at TSRI.
Murine neutrophils were isolated either from peripheral blood (PB) or
bonemarrow (BM ofWT orMmp9-KOC57BL/6mice). Briefly, cardiac
blood was collected into heparin-containing tubes and fractionated on a
discontinued 1.007/1.119 Histopaque gradient according to the
manufacturer’s instructions (Sigma, St. Louis, MO). Alternatively, PB
neutrophils were isolated with EasySepMouseNeutrophil Enrichment kit
from STEMCELLTechnologies (Vancouver, Canada) according to the
manufacturer’s instructions. BM, providing a rich source of neutrophils
[41], was flushed from femurs and tibias with DMEM–5% FBS.
Single-cell suspension was generated by gentle pipetting and washed
with Dulbecco's PBS. Then, neutrophils were purified by immuno-
magnetic isolation using biotinylated Ly6G mAb 1A8 (Biolegend, San
Diego, CA) and streptavidin-conjugated magnetic beads (Miltenyi
Biotec, San Diego, CA).
Isolated neutrophils were analyzed for purity by HEMA kit (Fisher
Scientific, Kalamazoo, MI) and/or immunofluorescent staining with
Ly6G mAb 1A8 (Biolegend). Isolated neutrophils with high levels of
purity were used immediately in the angiogenesis assays or for release
of their granule contents.
Generation of Murine Macrophages and Their Polarization
To generate BMDmacrophages, BMwas flushed from the femurs and
tibias of WT or Mmp9-KO C57BL/6 mice. To generate PB-derived
(PBD) macrophages, monocytes were isolated from cardiac blood with
EasySep Mouse Monocyte Enrichment kit from STEMCELL Technol-
ogies according to the manufacturer’s instructions. Murine BM cells and
PBmonocytes were plated onto tissue culture plates or Petri dishes at ~1 ×
106 cells per 1 ml of RPMI 1640 supplemented with 10% FBS, 50 nM
β-mercaptoethanol, and 10% conditioned medium (CM) from L929
fibrosarcoma cells, a rich source of macrophage colony-stimulating factor
(M-CSF) [42]. Culture medium was changed for a fresh one every 2 to 3
days to generate matureM0macrophages. On day 7,M1 phenotype was
induced by exchanging M-CSF–containing medium for a mixture of
100 ng/ml lipopolysaccharide and 20 ng/ml interferonγ;M2 polarization
was induced by 20 ng/ml recombinant murine interleukin-4 (IL-4)
(PeproTech, Rocky Hill, NJ).
In Vivo Angiogenesis Assay
To determine the angiogenic capacity of intact cells or their
secretates, we used a collagen onplant angiogenesis assay as described
[43]. Briefly, intact cells or soluble proteins coming from equivalent
number of cells (3 × 104/onplant) were incorporated into 2.1 mg/ml
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NJ) and 30-μl collagen droplets were polymerized over gridded
meshes, generating three-dimensional rafts (onplants) that were grafted
onto the chorioallantoic membrane of chick embryos (five to six
onplants per embryo). Phosphate-buffered saline (PBS) or serum-free
(SF) medium was used as a negative control. To inhibit the proteolytic
activity of murine MMP-9, recombinant murine TIMP-1 was
incorporated at 4 ng per onplant. After 72 hours, the growth of
newly developed blood vessels was recorded using a stereoscope. The
levels of angiogenesis were determined as angiogenic indices calculated
for each onplant as the ratio of number of grids with newly formed
blood vessels versus total number of scored grids. The data are presented
as fold difference of angiogenesis levels induced over PBS/SF medium
control. Fold difference data from independent experiments were
pooled and presented as means ± SEM.
Orthotopic Prostate Cancer Human Xenografts
and Murine Tumors
Nonobese Diabetic/Severe Combined Immunodeficiency (NOD/
SCID)mice were purchased fromTSRI breeding colony at the age of 3 to
4months. The PC-3 prostate cancer orthotopic xenografts were generated
in NOD/SCID mice as described [40]. PC-lo/diss and PC-hi/diss cells
were trypsinized, washed in D10 and then in SF DMEM, and
resuspended in SF DMEM at 1 × 108 cells per ml. Immunodeficient
male mice were anesthetized and approximately 10 μl of cell suspension
(1 × 106 cells) was implanted into the anterior lobe of surgically exposed
prostate gland.Within 3 to 6weeks, the tumor xenografts were excised and
either frozen on dry ice in the optimal cutting temperature compound
(Sakura FinetekUSA, Inc., Torrance, CA) or fixed in Zn-formalin (Fisher,
Kalamazoo, MI) for histologic examination and immunostaining. The
lungs were harvested and the levels of spontaneous metastasis of human
tumor cells were determined by quantitative polymerase chain reaction
detecting human-specific Alu repeats (Alu-qPCR) [40].
Murine tumorswere generated by subcutaneous implantation of 5×105
cells into the flank of anesthetized mice. L929 tumors were grown in
immunodeficientnu/numice, whereas B16 andLLC cells were implanted
into the syngeneic wild-type (WT) orMmp9-KO C57BL/6 mice. After
tumors reached approximately 1 to 1.5 cm in diameter, the mice were
sacrificed. Tumors were excised and either fixed in Zn-formalin for
histologic examination, frozen on dry ice in the optimal cutting
temperature solution for immunohistochemical analyses, or enzymatically
digested to provide the source of TAMs and TANs.
Isolation and Characterization of TAMs and TANs
TAMs and TANs were isolated frommurine tumors by magnetic bead
separation according to the manufacturer’s instruction (Miltenyi Biotec).
The excised tumors were cut into small pieces and subjected to amixture of
bacterial collagenases I and IV and dispase (each at 1.0 mg/ml) and
1 unit/ml ofDNase I (all from Sigma) in SFDMEM.Approximately 5ml
of enzymatic mixture were used for each gram of solid tumor. Cell
dissociation was achieved by incubation for 1 to 2 hrs at 37°C, with
occasional gentle agitation of the tube and pipetting of the contents
through a 5-ml serological pipette. Dissociated tumor cells were washed
once with D10, passed through 70-μm nylon mesh strainer (BD
Biosciences), and then washed twice with PBS, pH 7.2, supplemented
with 1% BSA (PBS-BSA; passed through a 0.22-μm filter). When
indicated, cell pellet was subjected to red blood cell lysis and then
washed in PBS-BSA. For TAM and TAN isolations, single-cell
suspensions at 4 × 107 cells per ml were incubated with 10 μg/mlbiotin-conjugated F4/80-specific or Ly6G-specific mAbs, respectively
(both mAbs from Biolegend). After 1-hour incubation on ice with
occasional agitation, the cells were washed twice with PBS-BSA and
incubated at 1 × 108 cells per ml with streptavidin-conjugatedmagnetic
microbeads (Miltenyi Biotec) at 9:1 (vol/vol) ratio. Cells were washed
once with ice-cold PBS-BSA, filtered through 40-μm nylon mesh
strainer, and applied, under magnetic field, to pre-washed Miltenyi
Macs separation LS columns at 5 × 107 to 10 × 107 cells per 0.5 ml per
column. Columns were washed five times with 1 ml of PBS-BSA and
flow-through fraction was collected for further analyses. To elute
magnetically separated cells, the columns were removed from magnetic
field and flushed with 6 ml of PBS-BSA. Eluted cells were washed and
subjected to further analyses.
Details on TAM and TAN isolations and their characterization by
flow cytometry are presented in the Supplementary Data file (see
Appendix A). The isolated cells with high purity (90-95%) were used
immediately in the in vivo angiogenesis assays and/or used for
accumulation of their respective secretates.
Generation of Neutrophil Releasates and Macrophage CM
Isolated neutrophils and TANs were induced to release their
proMMP-9 by incubation at 0.5 × 107 to 1.0 × 107 cells per ml PBS
for 1 hour at 37°C. The releasates were cleared from the cell ghosts by
centrifugation at 14,000 rpm for 10 minutes at 4°C and frozen in
aliquots at −80°C until use.
Isolated macrophages and TAMs were incubated in tissue culture
plates at 1 × 106/ml, first in D10 to allow the cells to adhere to plastic,
and then in SF DMEM to collect CM at 48 hours. Alternatively,
TAMs were kept D10, and the cells were analyzed for lineage-specific
markers by flow cytometry after 2- to 5-day incubation.
Statistical Analysis and Data Presentation
Statistical analyses were performed using Prism Software (Graph-
Pad, San Diego, CA). In bar graphs, data are presented as means ±
SEM from a representative experiment or several normalized
experiments, in which fold changes were calculated from the pooled
fold differences by taking ratios of numerical values for individual
measurements in experimental groups over the mean of control
group. The unpaired two-tailed Student’s t test was used to determine
significance (P b .05) in difference between data sets.
Supplementary Data
Supplementary Data file (see Appendix A) contains detailed
information on well-established procedures employed in this study,
including Western blot analysis, immunohistochemistry, cytologic and
immunofluorescent analyses of isolated cells, flow cytometry analysis of
TAMs for cell surfacemarkers, gelatin zymography, and gene expression
analysis by real-time quantitative reverse transcription–PCR analysis.
Results
MMP-9 Production by Murine Neutrophils and Macrophages
In preparation for an extensive in vivo analysis of MMP-9 production
by TANs and TAMs, we initially investigated and quantified MMP-9
production by normal murine mature neutrophils versus macrophages.
Double staining of non-fractionated PB indicated that Gr-1–positive
neutrophils manifest high levels of MMP-9, whereas Gr-1–negative
mononuclear cells appear MMP-9 negative (Figure 1A). Neutrophils
were isolated from PB and their purity was validated by HEMA staining
(Figure 1B, left) and Ly6G-specific immunofluorescent staining with
774 TANs and MMP-9-mediated tumor angiogenesis Deryugina et al. Neoplasia Vol. 16, No. 10, 2014mAb 1A8 (Figure 1C, left). Alternatively, the neutrophils were isolated
from BM, which provided a rich source of highly purified mature
granulocytes (Figure 1B, middle). Since murine PB has low numbers of
monocytes, BM was also used to generate murine macrophages.
Adherent BM cells were cultured in the presence of murine M-CSF toB
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by HEMA staining after 7- to 9-day incubation (Figure 1B, right).
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were represented by almost 100% of F4/80-positive macrophages
(Figure 1C, right).WT BM-Derived
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secretory granules, the intact neutrophils, isolated from either PB or BM
of WT mice, were brightly stained for murine MMP-9, whereas no
positive immunofluorescence for MMP-9 was detected in Ly6G
neutrophils isolated from the BM ofMmp9-KO mice (Figure 1D). In
contrast to WT neutrophils, WT BMD macrophages did not generate
any significant MMP-9 signal (Figure 1D, right).
Cell lysates from PB and BM neutrophils and BMD macrophages
were subjected to gelatin zymography to compare their levels of intra-
cellularMMP-9. Neutrophils contained MMP-9 in its zymogen form,
proMMP-9, represented by ~105-kDa monomers, ~130-kDa hetero-
dimers of proMMP-9 with NGAL, and higher molecular weight
complexes of an apparent molecular weight of ~270 kDa (Figure 1E).
Quantitative comparisons against known amounts of recombinant
murine proMMP-9 demonstrated that 1 × 106 of PB and BM
neutrophils accumulated up to 112.5 ± 17.7 ng (n = 2) and 88.9 ± 6.8
ng (n = 3) of proMMP-9, respectively. In contrast, lysed BMD
macrophages produced very weak gelatinolytic bands (Figure 1E),
corresponding to only 1.2 ± 0.5 ng (n = 3) of proMMP-9 per 1 × 106
cells, which represents less than 2% of MMP-9 stored in equivalent
number of neutrophils. ConfirmingMMP-9 nature of the zymographic
bands, neutrophils isolated from PB and BMofMmp9-KOmice as well
as macrophages derived from BM ofMmp9-KOmice did not show any
gelatinolytic bands (Figure 1E).
We next examined whether PB monocytes would differentiate into
macrophages capable of higher levels of MMP-9 than their BMD
counterparts. Isolated PBmononuclear cells were incubated withM-CSF
for 9 days to yield mature F4/80-positive macrophages. However, these
PBD macrophages also induced extremely low MMP-9 gelatinolytic
activity in comparison to PB neutrophils (Figure 1F).
The amounts of proMMP-9 secreted bymacrophages were compared
with those released by neutrophils. Quantitative zymographic analyses
demonstrated that 1 × 106 neutrophils from PB and BM released,
respectively, 61.1 ± 11.9 ng (n = 9) and 70.0 ± 13.7 ng (n = 5) of
proMMP-9 within 1 hour, whereas the same number of BMD or PBD
macrophages secreted only 4.4 ± 2.6 ng (n = 4) and 2.5 ± 0.4 ng (n = 2)
of proMMP-9 during a 2-day-long incubation (Figure 1, F–H).
Therefore, tissue-resident macrophages would require at least 30 days
for producing the same amount of proMMP-9 releasable by neutrophils
immediately on demand.
Together, these findings indicate that tissue-infiltrating neutrophils can
rapidly provide a rich source of proMMP-9 required for inducing
angiogenic responses in vivo. In contrast, tissue-resident macrophages
might need prolonged time to synthesize and secrete their proMMP-9 to
reach even threshold concentrations required for angiogenic stimulation.
MMP-9–Mediated Angiogenesis Induced In Vivo by Neutrophils
and Macrophages
Angiogenic potential of murine neutrophils and macrophages and
their proMMP-9 was analyzed in the well-established quantitativeFigure 1. Normal neutrophils are the major producer of MMP-9. (A
(green) and MMP-9 (red). Cell nuclei were highlighted with 4',6-di
Neutrophils were isolated from PB or BM of WT or Mmp9-KO mice,
mononuclear cells. Bars, 10 μm (B) HEMA staining. (C) Immunostaini
9. (E–H) Zymographic analysis of MMP-9. Recombinant murine proM
9. Arrows point to the 105-kDa monomers, ~130-kDa heterodimers
BMD-Mϕs and neutrophils isolated from PB or BM of WT orMmp9-K
and CM from WT PBD-Mϕs. (G) RL from PB and BM neutrophils isoassay involving live chick embryos grafted with three-dimensional
collagen onplants [43]. The angiogenic potential of mature BMD
macrophages (M0 phenotype) was quantified in comparison with
their M1- andM2-polarized counterparts. Whereas intact neutrophils
induced high levels of angiogenesis at 4.6 ± 0.9 fold excess versus no
cell control (P b .0001), fully differentiated M0 macrophages were
only moderately angiogenic, demonstrating a 2.2 ± 0.3 fold excess
over negative control (P b .0001; Figure 2A). Furthermore,
angiogenesis-inducing capacity of intact neutrophils but not M0
macrophages almost entirely depended on their MMP-9 competence
(Figure 2A).
Acquisition of M1 phenotype after interferon γ/lipopolysaccharide
treatment did not change significantly the relatively low angiogenic
capacity of M0 macrophages. Importantly, angiogenic potentials of
M0 and M1 macrophages from Mmp9-KO mice were similar to
those of their WT counterparts (Figure 2A), indicating that low
angiogenesis-inducing capacity of these two macrophage phenotypes
was independent of MMP-9 production. In contrast, induction of
M2 phenotype resulted in a significant increase of the angiogenic
capacity of the IL-4–treated M0 macrophages reflected in 3.1 ± 0.4
fold excess over no cell control (P b .0001). Furthermore, M2
macrophages from Mmp9-KO mice demonstrated a low angiogenic
potential, comparable to that of MMP-9–deficient M0 and M1
macrophages (Figure 2A). These findings point out that the enhanced
angiogenesis-inducting capacity of MMP-9–competent M2 macro-
phages was entirely dependent on their ability to produce MMP-9
and thus providing one of the molecular explanations for the known
proangiogenic potential of M2-polarized macrophages.
Remarkably close patterns were observed between the angiogenesis
levels induced by intact cells and their respective secretates (Figure 2, A
and B). Thus, the levels of angiogenesis induced by neutrophil releasates
were comparable to those induced by intact cells, including the
dependence on MMP-9 since neutrophil releasates from Mmp9-KO
mice induced angiogenesis at no-cell control levels (Figure 2B). Similar to
the pattern observed with intact macrophages, the M0 andM1 secretates
were only low to moderately angiogenic and independent of their genetic
ability to generate proMMP-9 (Figure 2B). In contrast, the M2
macrophage secretate induced enhanced levels of angiogenesis, exceeding
3.6 ± 0.4 fold the negative control (P b .0001) and demonstrating entire
dependence on MMP-9 genetic status (Figure 2B).
To correlate the levels of angiogenesis-inducing activity with the
levels of produced MMP-9 protein, we quantified proMMP-9
content in BM neutrophil releasates and secretates of M0, M1, and
M2 BMD macrophages by Western blot analysis. Within 2-hour
induction, 1 × 106 of WT neutrophils released 164.1 ± 48.1 ng of
proMMP-9 (n = 7), but surprisingly, the same number of M0, M1,
and M2 macrophages during a 48-hour-long incubation produced
only 4.8 ± 2.2 (n = 4), 11.5 ± 2.7 (n = 8), and 8.6 ± 2.1 ng (n = 9) of
proMMP-9, respectively (Figure 2C, top), which represents only 3%
to 7% of that released on demand by neutrophils.) Unfractionated PB from WT mice was immunostained for Gr-1
amidino-2-phenylindole dihydrochloride (blue). Bar, 5 μm. (B–D)
whereas macrophages (Mϕs) were generated from adherent BM
ng (green) for Ly6G or F4/80. (D) Immunostaining (green) for MMP-
MP-9 (Rec. MMP-9) provided standards for quantification ofMMP-
, and ~ 270-kDa multimers of proMMP-9. (E) Cell lysates (CL) of
O mice. (F) CL and releasates (RL) fromWT PB neutrophils and CL
lated from WT and Mmp9-KO mice. (H) CM from WT BMD-Mϕs.
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Figure 2. Angiogenic potential of neutrophils and M2 macrophages depends on production of proMMP-9. (A and B) Neutrophils and
macrophages (Mϕs), derived fromWT andMmp9-KO BM, were analyzed for their angiogenic potential in vivo as intact (3 × 104) cells (A) or
their secretates (B). Mature BMD-Mϕs (M0 phenotype) were polarized toward the M1 or M2 phenotype. In (B), recombinant TIMP-1 was
added toWT neutrophil releasate andM2Mϕ CM. Pooled data from three (A) and seven (B) independent experiments, each employing from
four to six embryos graftedwith four to six onplants per variant, are presented. Data are means ± SEM. *P b .05, **P b .005, ***P b .0001.
(C) Western blot analysis of MMP-9 (top) and TIMP-1 (bottom) produced by BM neutrophils and BMD-Mϕs was performed in
comparison with recombinant proMMP-9 (105 kDa) and TIMP-1 (28 kDa) standards. (D) Zymographic (top) andWestern blot analyses
of MMP-9 (middle) and TIMP-1 (bottom) secreted by Mϕs were performed in comparison with recombinant proMMP-9 (105 kDa) and
TIMP-1 (28 kDa) standards. Mature M0Mϕs were polarized toward the M1 or M2 phenotype. A portion of M2Mϕs was then reversed
toward the M1 phenotype. (E) Analysis of arginase-1 and iNOS expression in M1, M2, and M2→M1 repolarized Mϕs. (D) Angiogenic
potential of mature, polarized, and repolarized Mϕs was determined in vivo as described in A. One of two independent experiments
employing from five to seven embryos, each grafted with four to six onplants per variant, is presented. Bars are means ± SEM. *P b .05.
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Depends on Their Production of TIMP-1–Free proMMP-9
Since both the activation of human proMMP-9 and the
functional angiogenic activity of the resultant enzyme depend on
the levels of TIMP-1 bound to the zymogen [34,36,38], we
quantified how much TIMP-1 was produced by murine neutrophils
and macrophages (Figure 2C, bottom). In agreement with the
known lack of TIMP-1 expression in neutrophils [44], no TIMP-1
was detected in neutrophil releasate. In contrast, M0 and M1
macrophages produced TIMP-1 at levels exceeding the 1:1
stoichiometric MMP-9/TIMP-1 molar ratio, suggesting the pro-
duction of proMMP-9 fully complexed with TIMP-1. However,
polarization to M2 phenotype was accompanied by a remarkable
reduction of TIMP-1, indicating that murine M2 macrophages
secreted TIMP-deficient, angiogenic proMMP-9. Consistent with
this notion, the addition of exogenous TIMP-1 to M2 secretate
reduced its angiogenesis-inducing capacity down to the levels of the
Mmp9-KO M2 cells. Similarly, the angiogenesis-inducing capacity
of TIMP-free WT neutrophil releasate was also highly sensitive to
TIMP-1 addition (P b .005; Figure 2B).
To confirm that production of TIMP-1 is detrimental for the
ability of macrophages to induce angiogenesis, M0 macrophages were
first polarized toward M1 or M2 phenotypes, and then the M2
macrophages were repolarized toward M1 phenotype or kept in M2
state (Figure 2D). Consistent with the reciprocal pattern of inducible
nitric oxide synthase (iNOS) and arginase-1 expression in M1/M2
macrophages, M2→M1 repolarization resulted in the induction of
iNOS and disappearance of arginase-1 (Figure 2E). M2→M1
repolarization was not accompanied by any significant changes in
the production of proMMP-9 but resulted in a dramatic induction of
TIMP-1 (Figure 2D), expressed at levels characteristic of M1
macrophages. Importantly, M2→M1 repolarized macrophages
completely lost their enhanced angiogenic capacity and were
angiogenic only at the low background levels exhibited by M1
macrophages (Figure 2F).
Together, these results demonstrate that both neutrophils and
M2 macrophages uniquely produce TIMP-deficient proMMP-9,
and therefore, these two types of leukocytes can provide the
angiogenic MMP-9 to the sites of tissue inflammation, including
sites of tumor development.
TANs and TAMs in Human Prostate Cancer Xenografts
Relative contribution of TANs and TAMs to tumor angiogenesis and
metastasis was initially investigated in human prostate cancer xenografts
grown in NOD/SCID mice. Human prostate cancer PC-3 variants, PC-
hi/diss and PC-lo/diss, selected in vivo for high and low dissemination
capacities [40], were implanted into anterior prostates. At 6 weeks, the
mouse lungs were analyzed for levels of spontaneous metastasis, whereas
primary tumors were processed for quantitative analyses of inflammatory
leukocyte influxes as well as angiogenesis (Figure 3, A and B). Human-
specificAlu-qPCR confirmed the significant differential between the levels
of lung metastasis in PC-hi/diss versus PC-lo/diss variants (Figure 3B, left).
Whereas similar densities of F4/80-positive TAMswere observed between
PC-lo/diss and PC-hi/diss tumors, the density of Ly6G-positive TANs
was approximately 2.5- to 3.0-fold higher within PC-hi/diss xenografts
compared with PC-lo/diss counterparts (Figure 3, A and B,middle). This
differential in the TAN density was concomitant with a three-fold
differential in the density of lumen-containing angiogenic vessels in PC-
lo/diss versus PC-hi/diss xenografts (Figure 3, A and B, right), thuslinking the levels of inflammatory neutrophils with the levels of
tumor angiogenesis.
A significant 5.5-fold differential in the density of TANs versus
TAMs was also validated in PC-hi/diss tumors at 3 weeks (Figure 3C),
consistent with the notion that neutrophil influx and delivery of
highly angiogenic neutrophil MMP-9 at early times were associated
with the induction of tumor angiogenesis and development of a
metastasis-sustaining vasculature. Double staining of PC-hi/diss
tumor sections for murine MMP-9 along with either neutrophil-
specific Ly6G or macrophage-specific F4/80 indicated that leukocyte
MMP-9 was associated almost exclusively with neutrophils and not
with macrophages (Figure 3D). Thus, almost 100% of Ly6G-positive
TANs manifested significant overlap of their cell-specific 1A8 signal
with the MMP-9–specific signal (Figure 3D, top). Murine MMP-9
was also found associated with stromal fibrillar material localized
between tumor cells and, almost invariably, in the areas of neutrophil
congregation. In contrast, F4/80-positive TAMs demonstrated no
direct overlap with MMP-9 even in the areas of MMP-9–positive
matrix localization (Figure 3D, bottom). Quantitative analysis
indicated that 96.6 ± 2.3% (n = 3) of all MMP-9–positive tumor-
associated leukocytes were TANs, whereas almost 100% of TAMs
were negative for MMP-9, supporting the notion that TANs are the
main suppliers of angiogenesis-inducing MMP-9.
Biochemical and Functional Characterization of L929 TAMs
and Their Secreted MMP-9
To further investigate whether TANs or TAMs supply the
majority of angiogenesis-inducing proMMP-9 to the tumor
microenvironment, we compared the angiogenic capabilities of
TAMs and TANs isolated from a number of syngeneic mouse
tumors. We initially generated L929 tumors because L929
fibrosarcoma cells produce large amounts of the monocyte/
macrophage attractant, M-CSF [42]. L929 tumors developed a
robust network of angiogenic vessels and capillaries and also
recruited inflammatory cells that accumulated at the tumor border
and in islands within tumor interior (Figure 4A). Immunofluores-
cent staining of L929 tumors for leukocyte-specific antigens
illuminated large, island-like congregations of F4/80-positive
macrophages but only few Ly6G-positive neutrophils (Figure 4B),
and therefore L929 tumors were used to purify only TAMs.
L929 tumors yielded on average 29.0 ± 5.4 × 106 TAMs per 1 ×
108 cells of initial cell suspension (Table W1), indicating an
extremely high percentage of TAMs in this murine tumor type likely
due to overexpression of M-CSF. Flow cytometry of freshly isolated
and in vitro cultivated L929 TAMs confirmed their high purity by
staining for myeloid cell and macrophage antigens, including CD11b,
CD206/MMR, and F4/80 (Tables W1 and W2). L929 TAMs also
expressed high levels of arginase-1 and were negative for iNOS
(Figure 4C), a dual characteristic indicating an M2-skewed phenotype
of isolated TAMs. M2-skewed phenotype of L929 TAMs was also
corroborated by gene expression analysis, which showed that while
L929 tumor cells were negative for Arg1 and Mrc1, isolated L929
TAMs exhibited high expression levels of these two genes
characteristic of M2 macrophages (Figure 5A). Relatively high
levels of Agr1 and Mrc1 were also observed within dissociated
tumors (Figure 5A), consistent with high TAM representation in the
M-CSF–enriched L929 tumors.
Western blot analysis demonstrated that while original L929 tumor
cells did not produce any detectable levels of proMMP-9 or TIMP-1,
778 TANs and MMP-9-mediated tumor angiogenesis Deryugina et al. Neoplasia Vol. 16, No. 10, 2014the isolated L929 TAMs secreted proMMP-9 but no detectable
TIMP-1 (Figure 5B). Densitometry analyses indicated that 1 ×106
L929 TAMs secreted 3.4 ± 1.3 ng of TIMP-free proMMP-9 within
48-hour incubation (n = 6).
Although intact L929 TAMs induced moderate levels of
angiogenesis, their secreted products induced higher angiogenic levelsPC
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for Enhanced Angiogenesis
To further demonstrate that the proMMP-9 produced by TAMs was
responsible in large part for the enhanced angiogenesis-inducing capacity
of their secreted products, we employed WT andMmp9-KO C57BL/6
mice implanted with the syngeneic B16-F10 (B16) melanoma cells.
Isolation of TAMs fromB16 tumors grown inWT andMmp9-KO hostsFigure 3. Tumor dissemination and development of angiogenic vasc
recruitment of MMP-9–bearing neutrophils. (A) PC-lo/diss (top) and P
(left), infiltration by macrophages and neutrophils (middle), and tu
(brown) leukocytes and blood vessels are indicated by yellow arrowhe
of TAMs, TANs, and lumen-containing blood vessels in PC-lo/diss
independent experiments, each employing six mice per variant, ar
xenografts were double-stained for neutrophil-specific (Ly6G; green)
Relative density of TAMs and TANs, quantified in a total of 17 to 30
experiments, is presented as fold difference over TAM density (1.0). (
MMP-9 (red) and either neutrophil-specific (Ly6G) or macrophage-sp
boxed areas imaged at higher magnification. Bar, 25 μm. Small pan
rows) and TAMs (two bottom rows). White arrows point to MMP
mature neutrophils.yielded 3.5 ± 2.0 and 1.9 ± 0.3 × 106 TAMs per 1 × 108 primary tumor
cells, respectively (Table W1). Although lower than the average yields of
L929 TAMs, the B16 TAMs from either WT orMmp9-KO mice were
of high purity (Table W1) and also exhibited high levels of Arg1 and
Mrc1 (Figure 5D), indicating their M2-skewed phenotype.
Quantification of proMMP-9 production demonstrated that 1 × 106
of WT B16 TAMs secreted approximately 3.6 ± 0.9 ng of proMMP-9ulature in human PC-3 prostate cancer xenografts correlates with
C-hi/diss (bottom) xenografts were examined for overall histology
mor vasculature (right). Some of immunohistochemically-stained
ads. Bars, 200 μm. (B) Levels of lungmetastasis and relative density
versus PC-hi/diss tumors. Pooled data (means ± SEM) from two
e presented. *P b .05, **P b .005, ***P b .0001. (C) PC-hi/diss
and macrophage-specific (F4/80; red) markers. Bar, 50 μm. Graph:
tumor sections from four tumors harvested in two independent
D) Left: PC3-hi/diss tumor sections were double-stained for murine
ecific (F4/80) markers (green). Bar, 50 μm. Middle sections depict
els on the right depict examples of double-stained TANs (two top
-9–positive leukocytes with multi-lobed nuclei characteristic of
780 TANs and MMP-9-mediated tumor angiogenesis Deryugina et al. Neoplasia Vol. 16, No. 10, 2014within 48-hour incubation (n = 3), whileMmp9-KO B16 TAMs did not
produce any detectable MMP-9 protein (Figure 5E, top). However,
regardless of their Mmp9 genetic background, neither WT nor Mmp9-
KO TAMs secreted detectable amounts of TIMP-1 (Figure 5E, bottom),F
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potential of CM from WT B16 TAMs was completely abrogated by
exogenous TIMP-1, which diminished it to the levels induced by
Mmp9-KO B16 TAMCM. Importantly, the low levels of angiogenesis
induced byMmp9-KO B16 TAMs were not affected by the addition of
TIMP-1 (Figure 5F), emphasizing the specificity of the TIMP-1
diminishment of angiogenesis induced by WT B16 TAMs.Angiogenesis-Inducing Capacity of TANs and TAMs in Relation
to Their ProMMP-9
To compare angiogenesis-inducing capacities of TAMs and TANs
isolated from the same tumor, we turned to the well-established LLC
model. LLC tumors were generated in both WT and Mmp9-KO
C57BL/6 mice. Lineage-specific staining of WT-LLC tumors
illuminated both F4/80-positive TAMs and Ly6G-positive TANs,
with TAMs distributed more or less evenly throughout the stroma
and TANs found more frequently in tighter congregation
(Figure 6A). However, only WT TANs were simultaneously positive
for their Ly6G marker and MMP-9, whereas F4/80-positive TAMs
were essentially MMP-9 negative (Figure 6B). Highlighting specific-
ity of MMP-9 signal in WT tumors, MMP-9 staining was completely
negative in Mmp9-KO tumors (Figure 6C).
LLC tumor cells induced significant levels of inflammatory cell
influx reflected in higher yields of isolated TAMs and TANs compared
to B16 tumors, regardless of theMmp9 genetic status of hosts (Tables
W1 and W3). Isolated LLC TAMs and LLC TANs exhibited their
corresponding cell lineage morphology. Thus, HEMA-stained TAMs
appeared as relatively large cells (12-20 μm in diameter), with
numerous vacuoles within their abundant cytoplasm (Figure 6D,
left). In contrast, much smaller TANs (6-7 μm in diameter)
contained multi-lobed nuclei and a small rim of cytoplasm, all
characteristic of mature neutrophils (Figure 6D, right). Both types of
isolated tumor-associated leukocytes expressed their respective
lineage-specific F4/80 (TAMs) and Ly6G (TANs) markers
(Figure 6E).
Freshly isolated TAMs and TANs exhibited a dramatic differential
in expression of MMP-9, reflected in the bright MMP-9 immuno-
staining of TANs versus barely detectable signal in TAMs (Figure 6F).
Furthermore, LLC TAMs cultured for 2 days in vitro did not induce
expression of MMP-9 at levels above background as judged by a
double staining for MMP-9 and the general myeloid cell marker
CD11b (Figure 6G). Western blot analysis of 2-hour LLC TANFigure 5. Genetic, biochemical, and functional analyses of TAMs isola
Mrc1 (right) expression were determined in isolated L929 TAMs and
gene expression in L929 cells in culture (1.0). Pooled data from f
presented. (B) Samples of SF CM from 1 × 105 parental L929 cells (le
two magnetic bead columns, were analyzed in the same Western
per onplant) or their SF 48-hour CM was analyzed for angiogenesis-in
TIMP-1 (4 ng per onplant). Pooled data from five independent experim
six onplants per variant, are presented. Data are means ± SEM. *P b
Mrc1 (right) expression were determined in TAMs isolated from B
dissociated WT tumors in comparison with the levels of gene expre
independent experiments, each performed in duplicate, are presente
isolated from two WT and twoMmp9-KO tumors was analyzed by W
isolated from WT or Mmp9-KO mice was analyzed for angiogenesi
independent experiments, each employing from four to six embryos g
means ± SEM. ***P b .0001.releasate versus 48-hour LLC TAM CM demonstrated a significant
difference in proMMP-9 production (Figure 6H), thereby
confirming the dramatic differential in cell staining for MMP-9
(Figure 6, B and F). Quantification of independent TAN
preparations (n = 11) indicated that 1 × 106 LLC TANs contained
on average of 128.0 ± 27.0 ng of proMMP-9 (Figure 6H), which is
comparable with the amount of proMMP-9 shown for neutrophils
isolated from BM (164 ng/106 cells; Figure 2C). Remarkably, 1 × 106
LLC TAMs produced only 3.4 ± 1.3 ng of proMMP-9 during 48-hour
incubation, which was similar to low amounts of proMMP-9 produced
by TAMs isolated from both L929 and WT B16 tumors but ~40- to
50-fold lower than amounts of MMP-9 released by LLC TANs. Also
consistent with biochemical characteristics of TAMs from the other
tumor types, LLC TAMs produced neutrophil-like, TIMP-free
proMMP-9 (Figure 6H).
Both the intact WT LLC TANs and their releasates were highly
angiogenic, yielding angiogenesis at levels exceeding 3.5 ± 0.7 and 3.8 ±
1.0 fold over control levels, respectively (P b .001; Figure 6I).
Importantly, LLC TANs from Mmp9-KO mice produced low to non-
angiogenic releasates, indicating that the angiogenic potency of WT
LLC TANs was almost entirely dependent on their pre-stored
proMMP-9. In contrast, intact WT LLC TAMs induced low levels
of angiogenesis and only slightly higher levels were induced by their
CM (Figure 6I).
Within the tumor stroma, MMP-9–positive TANs were almost
invariably surrounded by MMP-9–positive fibrillar material
(Figure 7A), suggesting that TANs deposited their proMMP-9.
In contrast, F4/80-positive TAMs were not localized within or
near MMP-9–positive stroma unless smaller F4/80-negative cells
with neutrophil-like nuclei were in close proximity (Figure 7B).
These results provided further strong evidence that TANs, not
TAMs, are the major source of myeloid cell proMMP-9 in the
tumor microenvironment.
Since CM from WT-LLC TAMs appeared to be less angiogenic
compared with WT-B16 and L929 TAMs, we thought to
determine whether LLC TAMs were particularly sensitive during
their in vitro incubation to a deficiency in those cytokines that
regulate M2-skewed status of macrophages and consequently
attenuated their production of proMMP-9. Isolated WT LLC
TAMs were incubated with IL-4, a potent inducer of the M2
phenotype. After 48-hour incubation, non-treated and IL-4–
treated WT LLC TAMs were analyzed for their angiogenesis-
inducing capacity along with freshly isolated cells. Production ofted from L929 and B16 tumors. (A) Relative levels of Arg1 (left) and
enzymatically dissociated tumors in comparison with the levels of
our independent experiments, each performed in duplicate, are
ft lane) or L929 TAMs, isolated independently from two tumors on
blot for MMP-9 and TIMP-1. (C) Isolated L929 TAMs (3 × 104
ducing capacity. CM was incorporated alone or with recombinant
ents, each employing from four to six embryos grafted with four to
.05, **P b .001, ***P b .0001. (D) Relative levels of Arg1 (left) and
16 tumors grown in WT or Mmp9-KO mice and in enzymatically
ssion in parental B16 cells in culture (1.0). Pooled data from two
d. (E) CM from 1 × 105 parental B16 cells (left lane) or B16 TAMs
estern blot analysis for MMP-9 and TIMP-1. (F) CM from B16-TAMs
s-inducing capacity alone or with TIMP-1. Pooled data from three
rafted with four to six onplants per variant, are presented. Data are
782 TANs and MMP-9-mediated tumor angiogenesis Deryugina et al. Neoplasia Vol. 16, No. 10, 2014proMMP-9 was increased by approximately three-fold in IL-4–
treatedTAMswithout any induction of TIMP-1, reaching approximately
10 ng of TIMP-free proMMP-9 per 1 × 106 cells (Figure 8A).
Correspondingly, IL-4– “re-enforced” TAMs exceeded by 3.7 ± 0.7 foldA
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fibrosarcoma, melanoma, or lung carcinoma), TAMs produce
TIMP-deficient proMMP-9 and therefore can induce MMP-9–
dependent angiogenesis. However, neither MMP-9 production nor
angiogenic potential of TAMs match those of TANs rapidly
delivering their abundant pre-stored TIMP-free proMMP-9
at high local concentrations and therefore inducing high levels
of tumor angiogenesis.
Microarchitecture of Intratumoral Angiogenic Networks Depends
on the Host MMP-9
To relate directly the MMP-9–expressing TANs to a functional
angiogenic vasculature, LLC tumors from WT and Mmp9-KO mice
were analyzed for the presence of mature, lumen-containing blood
vessels. Tissue staining for endothelial cells indicated that LLC tumors
presented with CD31-positive vascular networks regardless of host
Mmp9 genetic background (Figure 9A, top). However, analysis at
higher magnifications revealed a dramatic underrepresentation of
mature, lumen-containing vessels in MMP-9–deficient tumors
(Figure 9A, bottom). Thus, LLC tumors from Mmp9-KO mice were
infused with small, less than 3 to 5 μm in size, collapsed capillaries
without any detectable lumen (Figure 9A, right), which constitutedFigure 6. Analysis of TAMs and TANs from LLC tumors grown i
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contrast, MMP-9–competent tumors contained four-fold higher
fraction of more mature, lumen-containing blood vessels compared
to tumors from Mmp9-KO mice (Figure 9B). Further differential
analysis confirmed an underdeveloped organization of angiogenic
vessels in the Mmp9-KO tumors, which had 85.2 ± 0.1% of vessels
with a lumen of less than b10 μm in diameter (Figure 9C). In
contrast, MMP-9–competent tumors had a significant proportion
of angiogenic vessels with lumens of 11 to 20 μm (more than 35%)
or N21 μm (more than 15%) in diameter. Quantified against all
angiogenic blood vessels, there was a substantial 11.3-fold
differential in the density of intratumoral blood vessels containing
N11 μm lumen between MMP-9–competent and Mmp9-KO
tumors (Figure 9C).
To investigate whether microarchitecture of angiogenic vessels
correlated with the density of pericytes, LLC tumors grown in WT or
Mmp9-KO mice were double-stained for endothelial (CD31) and
pericyte (NG2) markers (Figure 10A). Quantification of the ratio of
two immunofluorescence signals (NG2:CD31) indicated that the
lack of host MMP-9 in LLC tumors correlated with approximately
50% reduction in pericyte density (Figure 10B). Furthermore, the
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NG2-positive cells were either scattered within the stroma or located
in the vicinity of blood vessels presenting no lumen (Figure 10C).
Almost identical results were obtained when vascular-associated cells
were quantitatively analyzed with another pericyte marker, desmin
(Figure 10, D–F).
It is important to emphasize that the above-described effects of host
MMP-9 on tumor angiogenesis and specifically on the microarch-
itecture of angiogenic vessels and lumen support by pericytes did not
depend on the actual presence of TANs (or TAMs) since their yields
were comparable between the tumors grown in WT and Mmp9-KO
mice (Table W3). Taken together, our findings point to TANs as themajor contributors of proMMP-9 within the tumor microenviron-
ment, where it induces development of an angiogenic vasculature and
sustains its functional microarchitecture.
Discussion
Although high levels of neutrophils and macrophages have been
previously associated with tumor angiogenesis and malignant
progression in cancer patients [13–15,45–47], xenograft models
[10,37,38,48,49], and genetic models of cancer [23,32,33,50], a
quantitative investigation of TAM versus TAN contribution to the
delivery of critical and rate-limiting proangiogenic molecules such as
proMMP-9 has not been carried out. Herein, by employing four
different primary tumor models, including human prostate cancer
xenografts and two syngeneic murine transplant models involving
WT and Mmp9-KO hosts, we compared functional capacity of
TAMs and TANs to produce proMMP-9 and induce MMP-9–
mediated angiogenesis. Our results indicate that contrary to
conventional notion, it is not TAMs, but TANs that produce
abundant TIMP-free proMMP-9, which is readily available for rapid
release within the tumor microenvironment and unencumbered
activation into a powerful angiogenesis-inducing enzyme.
First, the differentials in levels of tumor angiogenesis and metastasis
between high and low disseminating human prostate cancer variants
directly correlated with significant difference in the density of TANs,
whereas the TAM representation was comparable between the two
tumor variants. Furthermore, when the same PC-hi/diss tumors were
double-stained for leukocyte lineage-specific markers and MMP-9, a
strong signal for MMP-9 was associated only with Ly6G-positive
TANs, not F4/80-positive TAMs. Interestingly, in scarce cancer
patient–related studies that specifically addressed the MMP-9
localization in the inflammatory leukocytes populating human
colon, pancreatic, and hepatocellular carcinomas, most of MMP-9
protein had also been localized to TANs [51–53].
Our previous findings demonstrated the unprecedented ability of PB
neutrophils and neutrophil proMMP-9 to induce physiologic angiogen-
esis [34,36]. Together, these results prompted us herein to quantitatively
compare functional capacity of TANs and TAMs to produce proMMP-9
and induce MMP-9–dependent tumor angiogenesis. Paradoxically,
TAMs both within tumor tissue and after isolation from either of three
histologically different tumor types represented by L929 fibrosarcoma,
B16 melanoma, and LLC carcinoma demonstrated near background
levels when probed for MMP-9. In contrast, TANs from WT LLC
tumors were packed with pre-stored proMMP-9, providing additional
evidence for their functional role in the delivery of angiogenic MMP-9 to
the site of tumor development. Furthermore, the amount of proMMP-9
produced by isolated TAMs even over extended time periods was 40- to
50-fold lower than that released almost immediately by isolated TANs, a
result solidifying the notion that TANs, and not TAMs, are responsible
for MMP-9–mediated angiogenesis in the tumor microenvironment,
especially at early stages of tumor development.
It appears important to emphasize that although our data identify
TANs as a major tumor-associated leukocyte type delivering a
specific angiogenesis-inducing molecule, namely TIMP-free MMP-
9, into the tumor microenvironment and also corroborate the
findings from several neutrophil depletion studies unequivocally
demonstrating critical roles of neutrophils in tumor progression
[10,33,37,38,54–56], the present study does not dispute the
diversified functions of TAMs in tumor growth and angiogenesis, in
particular at later stages in cancer progression.
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cells producing angiogenic proMMP-9 as well as on the biochemical
status of proMMP-9 produced by angiogenesis-inducing leukocytes.
Reflecting their full differentiation mode, TANs contained multi-
lobed nuclei, a small rim of cytoplasm, and a large MMP-9 cargo, all
of which are features of mature neutrophils. Since we showed that
BM-isolated neutrophils are also represented mainly by mature
MMP-9–loaded granulocytes, it is plausible that the majority of
TANs originate from the neutrophils that have egressed from BM to
PB and then infiltrated the tumor environment. Cytologic
examinations were also consistent with the mature state of TAMsin all four tumor models. Furthermore, positive expression of
arginase-1 and macrophage mannose receptor at both gene and
protein levels and the lack of iNOS expression allowed us to attribute
an M2 phenotype to the isolated TAMs.
According to the data presented herein, the M2-skewed TAMs
did not express any detectable TIMP-1 and therefore produced
their proMMP-9 as a TIMP-free proenzyme, which is consistent
with our previous in vitro findings with normal M2-polarized
human and murine macrophages [39]. The TIMP-free status of
proMMP-9 is an important biochemical characteristic required for
unencumbered and rapid activation and high angiogenic capacity of
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proMMP-9 was highly susceptible to inhibition by exogenous
TIMP-1, completely losing its relatively low-to-moderate angiogenesis-
inducing capacity.
Forced cytokine-induced polarization of human and murine
macrophages toward the M2 phenotype in vitro is associated witha dramatic down-regulation of TIMP-1 expression after exposure
to IL-4, IL-10, or IL-13 [39]. It is likely that, in vivo, these
cytokines not only negatively control the levels of TIMP-1
production by recruited inflammatory monocytes and mature
TAMs but also moderately regulate the levels of MMP-9 secretion.
Consistent with this suggestion, IL-4–treated TAMs responded
Neoplasia Vol. 16, No. 10, 2014 TANs and MMP-9-mediated tumor angiogenesis Deryugina et al. 787with increased proMMP-9, but not TIMP-1, production and,
correspondingly, with a significantly increased angiogenesis-
inducing capacity. These findings strongly suggest that the lack
of TIMP-1 production or substantial down-regulation of TIMP-1
gene expression in mature TAMs should constitute a distinguish-
ing feature of M2-skewed macrophages.
Having established that inflammatory TANs were the major source
of angiogenic proMMP-9, we further focused our study on the
involvement of proMMP-9 in the development and microarchitec-
ture of the induced angiogenic vasculature. Noteworthy, high levels of
metastasis in human prostate xenografts coincide with the develop-
ment of lumen-containing blood vessels and substantial influx of
MMP-9–expressing TANs, both in the orthotopic murine model
employed herein and also in the chick embryo spontaneous metastasis
model [38]. In patients with hepatocellular carcinoma, disease
progression directly correlates with tumor infiltration by MMP-9–
positive neutrophils and development of sinusoidal vasculature [53].
The notion that MMP-9 competence of inflammatory TANs could
determine the lumen-containing status of tumor vasculature was
demonstrated in this study by using syngeneic murine tumors
developing in MMP-9–deficient hosts. Thus, although the overall
levels of tumor angiogenesis were comparable with MMP-9–
competent tumors, the tumor vasculature developing in Mmp9-
KO mice was deficient in lumen-containing vessels and was
represented mainly by collapsed capillaries. In contrast, WT
tumors, which are infiltrated with MMP-9–delivering TANs,
developed blood vessels with lumens of 11 to 20 μm in diameter.
Importantly, angiogenic blood vessels with lumens of similar size
were also critical for intravasation and dissemination of human
epidermoid carcinoma in live animal models [57]. Therefore, it
appears that precisely these angiogenic vessel dimensions might be
required for accommodating the size and volume of actively
intravasating tumor cells.
Our data in the syngeneic LLC tumor model also indicate that
MMP-9 competence is required for proper coverage of lumen-
containing blood vessels by NG2- and desmin-positive pericytes,
which apparently stabilize the vessel wall, thus preventing it from
collapsing. This notion is in full agreement with the data showing
that inflammatory cell MMP-9 is responsible for pericyte recruit-
ment and support of the angiogenic vessel structure in human
neuroblastoma xenografts [25]. However, despite the requirement
for vessel wall support, the pericyte coverage of lumen-containing
vessels in MMP-9–competent tumors was clearly non-continuous,
which could be important for maintaining proper levels of vascular
permeability to facilitate intravasation of aggressive tumor cells and
their further dissemination. It should be also pointed out that the
negative effects of MMP-9 deficiency on tumor angiogenesis in
Mmp9-KO mice were not attributed to impaired representation of
TAMs and TANs in the tumor tissue. Furthermore, these dampening
effects were quite pronounced but partial, pointing out that additional
and compensatory mechanisms are involved or activated to support
tumor growth and metastasis.
In conclusion, our study provides strong evidence that not only is
the angiogenesis-inducing proMMP-9 molecule delivered to the
tumor microenvironment mainly by TANs and only partially by
TAMs but also that a unique TIMP-free proMMP-9 derived from
these distinct tumor-associated leukocytes profoundly regulates the
microarchitecture of angiogenic blood vessels in a way that facilitates
tumor cell dissemination. Our results also suggest that this distinctiveform of proMMP-9 could serve as a potential translational target in
pathologic conditions associated with acute or chronic tissue
inflammation, exemplified herein by neutrophils infiltrating devel-
oping tumors and inducing high levels of angiogenesis.
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